Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19093919 | METHODS FOR PREPARING MESENCHYMAL STEM CELLS | March 2025 | January 2026 | Abandon | 9 | 1 | 0 | No | No |
| 19029060 | CULTURE MEDIA BASED ON PROTEIN HYDROLYSATE AND A PROCESS FOR PREPARING THEREOF | January 2025 | January 2026 | Allow | 12 | 2 | 0 | Yes | No |
| 18992213 | OPTIMIZED METHOD FOR EXPANSION AND LARGE-SCALE PRODUCTION OF REGULATORY T CELLS (Tregs) | January 2025 | February 2026 | Allow | 13 | 2 | 0 | Yes | No |
| 18768392 | Compositions Derived from Placenta and Methods of Producing the Same | July 2024 | January 2026 | Allow | 19 | 3 | 1 | Yes | No |
| 18670347 | Formation of Three-Dimensional Organ from Pluripotent Stem Cells | May 2024 | March 2026 | Allow | 21 | 4 | 1 | No | No |
| 18437775 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF OLIGODENDROCYTE PROGENITOR CELLS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | No | No |
| 18395362 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | December 2023 | May 2024 | Allow | 5 | 1 | 0 | No | No |
| 18487457 | METHOD OF PRODUCING A MESODERMAL-LINEAGE PRIMITIVE STREAK CELL | October 2023 | March 2026 | Allow | 29 | 0 | 0 | No | No |
| 18231518 | SERUM-FREE AND XENO-FREE CULTURE MEDIUM FOR EXPANDING MESENCHYMAL STEM CELLS | August 2023 | February 2025 | Allow | 19 | 2 | 1 | Yes | No |
| 18226877 | METHODS OF GENERATING A SYNTHETIC EMBRYO | July 2023 | February 2024 | Allow | 6 | 1 | 0 | No | No |
| 18337454 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | June 2023 | February 2024 | Allow | 8 | 1 | 0 | Yes | No |
| 18296779 | CORTICAL INTERNEURONS AND OTHER NEURONAL CELLS PRODUCED BY THE DIRECTED DIFFERENTIATION OF PLURIPOTENT AND MULTIPOTENT CELLS | April 2023 | September 2024 | Allow | 17 | 1 | 1 | No | No |
| 18119682 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR EXPANDING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | March 2023 | August 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18119692 | CULTURE MEDIUM, COATING MATRIX AND METHOD FOR MATURING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | March 2023 | March 2025 | Allow | 24 | 4 | 2 | No | No |
| 18107308 | BIOMATERIALS FOR ENHANCED IMPLANT-HOST INTEGRATION | February 2023 | February 2026 | Allow | 36 | 1 | 0 | No | No |
| 18004764 | RECIPROCATING PRESSURE PERFUSION SYSTEM AND METHODS | January 2023 | June 2025 | Allow | 29 | 4 | 1 | Yes | No |
| 18002828 | METHODS FOR DERIVING DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLS | December 2022 | May 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18055327 | STEM CELL DERIVED ISLET DIFFERENTIATION | November 2022 | August 2024 | Allow | 21 | 2 | 0 | No | No |
| 17978936 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | November 2022 | May 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 17958234 | CELL CULTURE SUBSTRATES, METHODS AND USES THEREOF | September 2022 | May 2023 | Allow | 8 | 2 | 0 | No | No |
| 17819886 | TREATMENT OF MEDICAL CONDITIONS BY STEM CELL TRANSPLANTS AND STEM CELL ACTIVATION | August 2022 | March 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17879390 | CHEMICALLY DEFINED SERUM REPLACEMENTS FOR CELL CULTURE | August 2022 | February 2023 | Allow | 7 | 1 | 1 | No | No |
| 17806207 | PLATELET RICH PLASMA FORMULATIONS | June 2022 | January 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17747431 | CELLULAR SEEDING AND CO-CULTURE OF A THREE DIMENSIONAL FIBROBLAST CONSTRUCT | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17741355 | PARTICULATE LYOPHILIZED PLATELET LYSATE COMPOSITIONS | May 2022 | October 2025 | Allow | 41 | 2 | 1 | Yes | No |
| 17732227 | METHODS FOR PRODUCING CELL POPULATIONS WITH INCREASED NUCLEIC ACID UPTAKE | April 2022 | May 2024 | Abandon | 25 | 4 | 1 | Yes | No |
| 17725034 | DEVICES, SYSTEMS AND METHODS FOR INHIBITING INVASION AND METASTASES OF CANCER | April 2022 | September 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17720279 | METHOD FOR PROMOTING GROWTH OF PARIETAL DECIDUAL BASALIS-MESENCHYMAL STEM CELLS (PDB-MSCs) | April 2022 | October 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17715082 | BROWN ADIPOCYTE PROGENITORS IN HUMAN SKELETAL MUSCLE | April 2022 | August 2025 | Abandon | 40 | 1 | 1 | No | No |
| 17705159 | METHODS AND COMPOSITIONS FOR T-CELL COCULTURE POTENCY ASSAYS AND USE WITH CELL THERAPY PRODUCTS | March 2022 | December 2025 | Allow | 44 | 5 | 1 | No | Yes |
| 17695546 | Engineered Intestinal Tissue and Uses Thereof | March 2022 | October 2025 | Allow | 43 | 2 | 0 | No | No |
| 17695538 | Engineered Intestinal Tissue and Uses Thereof | March 2022 | March 2025 | Allow | 36 | 2 | 0 | No | No |
| 17670124 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | February 2022 | May 2024 | Allow | 28 | 1 | 0 | No | No |
| 17668746 | MULTIPLE ANTIGEN SPECIFIC CELL THERAPY METHODS | February 2022 | May 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17592184 | PERICYTE CELL EXOSOMES | February 2022 | November 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17582704 | MATERIALS AND METHODS FOR GENERATING THERAPEUTIC MESENCHYMAL STEM CELLS | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17566179 | CELL CULTURE SUBSTRATES, METHODS AND USES THEREOF | December 2021 | August 2022 | Allow | 7 | 1 | 1 | No | No |
| 17559539 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES | December 2021 | August 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17559545 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES | December 2021 | June 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17559583 | METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF A STEM CELL AND THERAPEUTIC USES | December 2021 | January 2025 | Allow | 37 | 0 | 1 | No | No |
| 17617257 | AUTOMATED T CELL CULTURE | December 2021 | October 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17616994 | CARDIOMYOCYTES AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | December 2021 | July 2023 | Allow | 19 | 2 | 1 | No | Yes |
| 17613941 | SERUM-FREE POLYPEPTIDE COMPOSITION FOR PROMOTING PROLIFERATION OF MESENCHYMAL STEM CELLS | November 2021 | May 2023 | Abandon | 18 | 2 | 0 | No | No |
| 17613130 | REPROGRAMMING OF LIPID METABOLISM TO INHIBIT T CELL SENESCENCE AND ENHANCE TUMOR IMMUNOTHERAPY | November 2021 | October 2025 | Allow | 46 | 2 | 1 | No | No |
| 17524905 | LARGE SCALE CELL MANUFACTURE SYSTEM | November 2021 | May 2025 | Abandon | 42 | 2 | 0 | No | No |
| 17472220 | STEM CELL DERIVED ISLET DIFFERENTIATION | September 2021 | May 2022 | Allow | 8 | 1 | 0 | Yes | No |
| 17447007 | CELL STRUCTURE, CELL CULTURE, AND MANUFACTURING METHOD OF A CELL STRUCTURE | September 2021 | February 2025 | Allow | 41 | 3 | 0 | No | No |
| 17447004 | MANUFACTURING METHOD OF A CELL STRUCTURE | September 2021 | March 2023 | Allow | 18 | 0 | 0 | No | No |
| 17466228 | Method For Reducing Differentiation Resistance Of Pluripotent Stem Cells | September 2021 | October 2024 | Abandon | 37 | 2 | 0 | Yes | No |
| 17394744 | COMPOSITIONS DERIVED FROM PLACENTA AND METHODS OF PRODUCING THE SAME | August 2021 | April 2024 | Allow | 32 | 2 | 0 | No | No |
| 17424144 | PREVENTING, AND SUPPRESSING PROGRESSION OF, RETINAL DISEASE, IMPROVING VISUAL COGNITIVE BEHAVIORAL FUNCTION, AND STRENGTHENING VISUAL FUNCTION | July 2021 | June 2025 | Abandon | 47 | 2 | 1 | No | No |
| 17416340 | A METHOD FOR INCREASING POPULATION OF SPERMATOGONIAL STEM CELLS | June 2021 | May 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17346980 | PRECURSORY REGULATORY CYTOTROPHOBLAST CELLS AND USES THEREOF | June 2021 | May 2024 | Allow | 35 | 2 | 1 | No | No |
| 17322672 | Methods and Compositions for the Clinical Derivation of an Allogenic Cell and Therapeutic Uses | May 2021 | May 2024 | Abandon | 36 | 1 | 1 | No | No |
| 17292411 | METHODS FOR ISOLATING AND EXPANDING CELLS | May 2021 | July 2025 | Allow | 50 | 2 | 0 | No | No |
| 17239513 | TREATMENT OF MEDICAL CONDITIONS BY STEM CELL TRANSPLANTS AND STEM CELL ACTIVATION | April 2021 | August 2022 | Abandon | 16 | 1 | 1 | No | No |
| 17235910 | CELL DIFFERENTIATION MEDIUM COMPOSITION, HIGH SECRETION INSULIN-PRODUCING CELLS AND PREPARATION METHOD THEREOF | April 2021 | September 2024 | Allow | 41 | 2 | 1 | No | No |
| 17287054 | CULTURE MEDIUM COMPRISING KETO ACIDS | April 2021 | March 2025 | Abandon | 47 | 3 | 1 | No | No |
| 17224191 | MULTI-LAYER AIRWAY ORGANOIDS AND METHODS OF MAKING AND USING THE SAME | April 2021 | April 2025 | Allow | 48 | 4 | 0 | Yes | No |
| 17216926 | Method for Screening for Platelet Production Promoters | March 2021 | January 2024 | Allow | 33 | 2 | 0 | No | No |
| 17213423 | BIOMATERIALS FOR ENHANCED IMPLANT-HOST INTEGRATION | March 2021 | September 2021 | Allow | 5 | 1 | 0 | No | No |
| 17208917 | Compositions And Methods For Epithelial Stem Cell Expansion And Culture | March 2021 | August 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17207057 | ULTRASOUND-BASED PATTERNING OF PARTICLES AND CELLS WITHIN FLUID MATRICES | March 2021 | September 2024 | Allow | 42 | 2 | 0 | No | No |
| 17198081 | MATRICES COMPRISING A MODIFIED POLYSACCHARIDE | March 2021 | February 2024 | Allow | 35 | 2 | 1 | No | No |
| 17196063 | MATURATION OF MAMMALIAN HEPATOCYTES | March 2021 | October 2023 | Abandon | 31 | 0 | 1 | No | No |
| 17183927 | PLACENTAL TISSUE COMPOSITIONS AND METHODS | February 2021 | November 2024 | Allow | 44 | 2 | 1 | No | No |
| 17165144 | TISSUE MATRIX MATERIALS AND ENZYMATIC ADHESIVES | February 2021 | May 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17161302 | METHODS OF MEDIATING MACROPHAGE PHENOTYPES | January 2021 | April 2025 | Allow | 50 | 4 | 1 | No | No |
| 17153458 | COMPOSITIONS AND METHODS OF CRYOPRESERVING CELLS | January 2021 | June 2025 | Allow | 52 | 3 | 0 | No | No |
| 17146089 | IMMUNOISOLATION DEVICE | January 2021 | July 2023 | Allow | 30 | 2 | 0 | No | No |
| 17252272 | Production Method for Culture Supernatant Preparation | December 2020 | August 2024 | Allow | 44 | 2 | 1 | No | No |
| 17058747 | LYSIS COIL APPARATUS AND USES THEREOF FOR ISOLATION AND PURIFICATION OF POLYNUCLEOTIDES | November 2020 | September 2025 | Allow | 58 | 3 | 0 | No | No |
| 16951452 | INJECTION MOLDING TO GENERATE COMPLEX HYDROGEL GEOMETRIES FOR CELL ENCAPSULATION | November 2020 | April 2025 | Allow | 53 | 4 | 1 | Yes | No |
| 17054114 | STEM CELL-DERIVED ALPHA CELLS AND METHODS OF GENERATING SAME | November 2020 | October 2024 | Abandon | 47 | 2 | 1 | No | No |
| 17054001 | THERAPEUTIC AGENT FOR SPINAL CORD INJURY | November 2020 | February 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17077134 | CELL CULTURE MEDIUM | October 2020 | September 2023 | Allow | 35 | 1 | 1 | No | No |
| 17049397 | METHOD FOR XENO-FREE GENERATION OF A POPULATION OF HMPC | October 2020 | January 2025 | Allow | 51 | 3 | 1 | No | No |
| 17071599 | VIABLE DISC REGENERATIVE COMPOSITION AND METHOD OF MANUFACTURE AND USE | October 2020 | December 2022 | Allow | 26 | 1 | 0 | No | No |
| 17066546 | MATURATION OF MAMMALIAN HEPATOCYTES | October 2020 | April 2023 | Abandon | 30 | 1 | 0 | No | No |
| 17066135 | MESENCHYMAL STEM CELL STORING OR TRANSPORT FORMULATION AND METHODS OF MAKING AND USING THE SAME | October 2020 | July 2024 | Abandon | 45 | 4 | 1 | No | Yes |
| 17045471 | SELECTIVE ENRICHMENT OF HIGH-QUALITY DNA INTACT SPERMS FROM A SEMEN SAMPLE | October 2020 | December 2023 | Allow | 38 | 1 | 1 | No | No |
| 17043613 | IMPROVED MULTIPLE ANTIGEN SPECIFIC CELL THERAPY METHODS | September 2020 | October 2021 | Allow | 13 | 1 | 0 | Yes | No |
| 17041672 | HUMAN PLURIPOTENT STEM CELL DERIVED NEURODEGENERATIVE DISEASE MODELS ON A MICROFLUIDIC CHIP | September 2020 | November 2024 | Allow | 49 | 1 | 1 | No | No |
| 17022897 | TREATMENT OF DISC DEGENERATIVE DISEASE AND STIMULATION OF PROTEOGLYCAN SYNTHESIS BY FIBROBLAST CONDITIONED MEDIA AND FORMULATIONS THEREOF | September 2020 | April 2023 | Allow | 31 | 0 | 1 | No | No |
| 16980637 | Cell products with improved stability and uses thereof | September 2020 | May 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16947991 | Method for slowing down aging in women by prolonging ovarian function. | August 2020 | March 2021 | Allow | 7 | 1 | 0 | No | No |
| 16990838 | METHODS AND COMPOSITIONS FOR AESTHETIC AND COSMETIC TREATMENT AND STIMULATING HAIR GROWTH | August 2020 | May 2022 | Abandon | 21 | 4 | 0 | No | No |
| 16984069 | HUMAN NIPPLE AREOLAR COMPLEX EXTRACELLULAR MATRIX SCAFFOLD AND METHODS RELATING THERETO | August 2020 | August 2022 | Allow | 25 | 0 | 0 | No | No |
| 16942580 | SYNTHETIC HYDROGELS FOR ORGANOGENESIS | July 2020 | May 2024 | Allow | 45 | 2 | 1 | No | No |
| 16918838 | CELL CULTURE MEDIA AND METHODS | July 2020 | September 2024 | Allow | 50 | 1 | 1 | No | No |
| 16958160 | Method for preparing BAP or BA cells | June 2020 | May 2023 | Abandon | 35 | 0 | 1 | No | No |
| 16954506 | IMMUNE CELL ORGANOID CO-CULTURES | June 2020 | August 2025 | Allow | 60 | 4 | 1 | No | No |
| 16900830 | SYNTHETIC TUMOR MICROENVIRONMENT TO REGULATE CANCER CELL BEHAVIOR | June 2020 | July 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16772666 | METHODS FOR OBTAINING MUSCLE DERIVED CELLS | June 2020 | December 2022 | Allow | 30 | 1 | 1 | No | No |
| 16891856 | CULTURE CONDITIONS TO PROLONG/ENHANCED ENDODERMAL CELL TYPE FOR CELL TRANSPLANTATION | June 2020 | April 2023 | Allow | 34 | 1 | 0 | No | No |
| 16887223 | TUBULAR TISSUE CONSTRUCT AND A METHOD OF PRINTING | May 2020 | February 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16768348 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF OLIGODENDROCYTE PROGENITOR CELLS | May 2020 | February 2024 | Allow | 45 | 2 | 1 | No | No |
| 16768019 | Formation of Three-Dimensional Organ from Pluripotent Stem Cells | May 2020 | February 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 16764381 | METHOD FOR INDUCING DIFFERENTIATION INTO AND PRODUCING BEIGE AND WHITE ADIPOCYTES | May 2020 | October 2022 | Allow | 29 | 1 | 0 | No | No |
| 16868905 | Precursory Regulatory Cytotrophoblast Cells and Uses Thereof | May 2020 | June 2021 | Allow | 13 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JOHNSON, KARA D.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 66.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner JOHNSON, KARA D works in Art Unit 1632 and has examined 223 patent applications in our dataset. With an allowance rate of 76.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 38 months.
Examiner JOHNSON, KARA D's allowance rate of 76.7% places them in the 43% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by JOHNSON, KARA D receive 2.28 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JOHNSON, KARA D is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +16.3% benefit to allowance rate for applications examined by JOHNSON, KARA D. This interview benefit is in the 57% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 27.2% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 47.1% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 83.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 55.8% are granted (fully or in part). This grant rate is in the 57% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.